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Supplementary Figure 1 Plasmid maps of BIA expression constructs. Heterologous cDNA sequences 
are expressed in yeast from constitutive TEF1 promoters on high-copy plasmids with different selection 
markers. The expression systems are used for the combinatorial expression of 6OMT, CNMT, and 4’OMT 
enzyme variants. 
Production of benzylisoquinoline alkaloids in Saccharomyces cerevisiae. KM Hawkins, CD Smolke.
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Supplementary Figure 2 LC-MS/MS analysis of the growth media of engineered yeast strains supplemented with 1 mM fed substrate 
and grown for 48 h confirms individual enzyme activities. (a) Characterization of 6OMT fed norlaudanosoline (left) and laudanosoline
(right). Left, extracted ion chromatograms for m/z = 302 are shown for CSY450 (red) and CSY451 (black). Right, extracted ion 
chromatogram for m/z = 316 is shown for CSY450 and is representative of CSY451. (b) Characterization of CNMT fed 
norlaudanosoline (left) and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (right). Left, extracted ion chromatograms for m/z = 302 are 
shown for CSY452 (red) and CSY453 (black). Right, extracted ion chromatograms for m/z = 208 are shown for CSY452 (red) and 
CSY453 (black). (c) Characterization of 4’OMT fed norlaudanosoline (left) and laudanosoline (right). Left, extracted ion chromatogram 
for m/z = 302 are shown for CSY454 (red) and CSY455 (black). The 4’OMT reaction product (m/z = 302) appears to contain a mixture 
of norlaudanosoline methylated at both the 6-OH and 4’-OH positions with major fragments of m/z = 164 and 178 observed. The 
unexpected m/z = 178 ion is believed to be due to a co-eluting impurity in the norlaudanosoline with the parent ion m/z = 314. Right, 
extracted ion chromatogram for m/z = 316 is shown for CSY454 and is representative of CSY455. The fragmentation pattern of the 
4’OMT reaction product does not show evidence of non-specific methylation. 
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Supplementary Figure 3 Western blot analysis confirms protein expression of 6OMT, CNMT, and 
4’OMT enzymes. Enzyme levels are comparable to levels of a yeast-enhanced GFP variant (yEGFP) 
expressed from the same construct (within ~2-3-fold signal). All proteins were expressed behind the 
TEF1 promoter on high-copy plasmids with a C-terminal V5 epitope tag. The blot was incubated with 
the Anti-V5 HRP antibody and a chemiluminescent assay was used for signal detection. Each lane was 
loaded with ~50 μg total protein. The CNMT variants are the most highly expressed and/or stable of the 
recombinant enzymes. At higher concentrations, degradation products were visible from the TfCNMT, 
indicating that this protein may be subject to proteolysis in yeast, although the full-length protein still 
dominates.
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Supplementary Figure 4 BIA metabolites accumulate in the growth media. Analysis of norlaudanosoline
(substrate) and reticuline (product) concentrations in cell extracts and growth media support a passive diffusion 
transport mechanism for BIA metabolites. Data shown is a 1:10 dilution of the growth media (norlaudanosoline, 
red; reticuline, blue) and a ~1:2 dilution of the cell extract (norlaudanosoline, green; reticuline, magenta) of 
CSY288 supplemented with 1 mM norlaudanosoline and grown for 48 h. Ratios of product to substrate and 
extracellular versus intracellular norlaudanosoline concentrations are shown as calculated by LC-MS peak 
areas. Chromatograms and calculations are representative of two independent experiments ± s.d.
Supplementary Figure 5 LC-MS chromatograms of the growth media of (a) CSY288 supplemented with 2 mM norlaudanosoline
and (b) CSY410 supplemented with 2 mM laudanosoline and grown for 48 h showing impurities and degradation products in the 
sample. (a) The total ion chromatogram is shown in black and the extracted ion chromatogram for norlaudanosoline (MS 288) is 
shown in purple. The major impurities are MS 314 shown in green and MS 316 shown in blue; reticuline (MS 330) is shown in red. 
The same 314 and 316 ions are observed in the wild-type strain supplemented with norlaudanosoline (inset). (b) The total ion 
chromatogram is shown in black and the extracted ion chromatogram for laudanosoline (MS 302) is shown in purple. The major 
impurity is MS 300 shown in green; the intermediate methyl-laudanosoline (MS 316) is shown in magenta; the intermediate reticuline
(MS 330) is shown in cyan; and the intermediate tetrahydrocolumbamine (MS 342) is shown in blue. The same 300 ion is observed in 
the wild-type strain supplemented with laudanosoline (inset). All detectable BIA metabolites elute in this time frame with the rest of 
the spectra relatively flat.
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Supplementary Table 1. A description of engineered yeast strains used in this work.  
Strain Plasmid(s) Integrated constructs Plasmid-based constructs
CSY288 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT
CSY307 pCS827, pCS830 PTEF1 -Ps6OMT , PTEF1 -PsCNMT , PTEF1 -Ps4'OMT
CSY308 pCS828, pCS830 PTEF1 -Ps6OMT , PTEF1 -TfCNMT , PTEF1 -Ps4'OMT
CSY309 pCS829, pCS830 PTEF1 -Tf6OMT , PTEF1 -PsCNMT , PTEF1 -Ps4'OMT
CSY310 pCS772, pCS830 PTEF1 -Tf6OMT , PTEF1 -TfCNMT , PTEF1 -Ps4'OMT
CSY311 pCS827, pCS831 PTEF1 -Ps6OMT , PTEF1 -PsCNMT , PTEF1 -Tf4'OMT
CSY312 pCS828, pCS831 PTEF1 -Ps6OMT , PTEF1 -TfCNMT , PTEF1 -Tf4'OMT
CSY313 pCS829, pCS831 PTEF1 -Tf6OMT , PTEF1 -PsCNMT , PTEF1 -Tf4'OMT
CSY314 pCS772, pCS831 PTEF1 -Tf6OMT , PTEF1 -TfCNMT , PTEF1 -Tf4'OMT
CSY325 his3 ::PGAL1-10 -Ps6OMT -loxP -Kan
R, leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -
Ps4'OMT , gal2 ::HIS3
CSY326 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PGAL1-10 -Ps4'OMT -
loxP -LEU2 , gal2 ::HIS3
CSY327 his3 ::PTEF1 -Ps6OMT , leu2 ::PGAL1-10 -PsCNMT -loxP -URA3 , ura3 ::PTEF1 -
Ps4'OMT , gal2 ::HIS3
CSY328 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PGAL1-10 -Tf4'OMT -
loxP -LEU2 , gal2 ::HIS3
CSY329 his3 ::PGAL1-10 -Tf6OMT -loxP -LEU2 , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -
Tf4'OMT , gal2 ::HIS3
CSY334 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT
CSY336 pCS1018 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT PTEF1 -PsBBE
CSY337 pCS1070 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT PTEF1 -PsBBE , PTEF1 -TfS9OMT 
CSY338 pCS1018 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT PTEF1 -PsBBE
CSY339 pCS1070 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT PTEF1 -PsBBE , PTEF1 -TfS9OMT 
CSY399 pCS1018, pCS953, pCS1058 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT PTEF1 -PsBBE , PTEF1 -TfS9OMT , PTEF1 -TfCYP719A , PTEF1 -AtATR1
CSY400 pCS1018, pCS953, pCS1058 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT PTEF1 -PsBBE , PTEF1 -TfS9OMT , PTEF1 -TfCYP719A , PTEF1 -AtATR1
CSY410 pCS1018, pCS953 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT , 
trp1 ::PTEF1 -AtATR1 -loxP -Kan
R
PTEF1 -PsBBE , PTEF1 -TfS9OMT , PTEF1 -TfCYP719A
CSY424 pCS782 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT PTEF1 -yCYP2D6
CSY425 pCS782 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT , 
trp1 ::PTEF1 -AtATR1 -loxP -Kan
R
PTEF1 -yCYP2D6
CSY428 ura3:: PTEF1 -yEGFP3-loxP-LEU2
CSY429 ura3:: PGAL1-10 -yEGFP3-loxP-LEU2, gal2:: Kan
R
CSY448 his3 ::PTEF7mut -Ps6OMT , leu2 ::PTEF7mut -PsCNMT , ura3 ::PTEF7mut -
Ps4'OMT
CSY449 his3 ::PTEF7mut -Ps6OMT , leu2 ::PTEF7mut -PsCNMT , ura3 ::PTEF7mut -
Tf4'OMT  
 
CSY450 pCS650 PTEF1 -Ps6OMT
CSY451 pCS677 PTEF1 -Tf6OMT
CSY452 pCS597 PTEF1 -PsCNMT
CSY453 pCS678 PTEF1 -TfCNMT
CSY454 pCS830 PTEF1 -Ps4'OMT
CSY455 pCS831 PTEF1 -Tf4'OMT
CSY456 his3 ::PTEF1 -Tf6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT
CSY458 his3 ::PTEF7mut -Tf6OMT , leu2 ::PTEF7mut -PsCNMT , ura3 ::PTEF7mut -
Tf4'OMT
CSY463 pCS781 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT PTEF1 -hCYP2D6
CSY464 pCS1320 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Tf4'OMT PTEF1 -yCYP2D6:yCPR1  (fusion protein)
CSY465 pCS781, pCS1035 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT PTEF1 -hCYP2D6 , PTEF1 -yCPR1
CSY466 pCS781, pCS1058 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT PTEF1 -hCYP2D6 , PTEF1 -AtATR1
CSY489 pCS781 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT , 
trp1 ::PTEF1 -hCPR-loxP -LEU2
PTEF1 -hCYP2D6
CSY490 pCS1421 his3 ::PTEF1 -Ps6OMT , leu2 ::PTEF1 -PsCNMT , ura3 ::PTEF1 -Ps4'OMT PTEF1 -hCYP2D6:hCPR1  (fusion protein)  
 
 
Supplementary Table 2. Primer sequences used to make stable integrations of enzyme constructs, GAL2 knockouts, 
and qRT-PCR. Restriction sites are underlined.  
 
Primer name Sequence
TEF.fwd ATAAAAGCTTACATATGCATAGCTTCAAAATGTTTCTACTCC 
TEF.rev TGCTAGCGTTTAAACGAATTCTGGATCCATCCTAGGAAAACTTAGATTAGATTGCTATGC 
CYC1.fwd ATGGATCCAGAATTCGTTTAAACGCTAGCACCCGGGGAGGGCCGCATCATGTAATTAGTT 
CYC1.rev ATAACTGCAGAGTCGACGGCCGCAAATTAAAGCCTTCGA 
HISint.fwdA TATACTAAAAAATGAGCAGGTGTCGGGGCTGGCTTAACTATGCGGCATCA 
HISint.revA TATATATATCGTATGCTGCAGCTCTGGCTTATCGAAATTAATACGACTCACTA 
HISint.fwdB ATTGGCATTATCACATAATGAATTATACATTATATAAAGTAATGTGATTTCTTCGAAGAATATACTAAAAAATGAGCAGG 
HISint.revB AGTATCATACTGTTCGTATACATACTTACTGACATTCATAGGTATACATATATACACATGTATATATATCGTATGCTGCAGCT 
LEUint.fwdA AGCAATATATATATATATATTGTCGGGGCTGGCTTAACTATGCGGCATCA 
LEUint.revA AGTTTATGTACAAATATCATAACTGGCTTATCGAAATTAATACGACTCACTA 
LEUint.fwdB TTTTCCAATAGGTGGTTAGCAATCGTCTTACTTTCTAACTTTTCTTACCTTTTACATTTCAGCAATATATATATATATAT 
LEUint.revB TACCCTATGAACATATTCCATTTTGTAATTTCGTGTCGTTTCTATTATGAATTTCATTTATAAAGTTTATGTACAAATATCATAA 
URAint.fwdA ACTGCACAGAACAAAAACCTTGTCGGGGCTGGCTTAACTATGCGGCATCA 
URAint.revA AGTTTAGTATACATGCATTTACTGGCTTATCGAAATTAATACGACTCACTA 
URAint.fwdB GGTATATATACGCATATGTGGTGTTGAAGAAACATGAAATTGCCCAGTATTCTTAACCCAACTGCACAGAACAAAAACCT 
URAint.revB AATCATTACGACCGAGATTCCCGGGTAATAACTGATATAATTAAATTGAAGCTCTAATTTGTGAGTTTAGTATACATGCATTTA
GAL.fwd ATAAAGCTTACATATGTCTAGAAAATTCCTTGAATTTTCAAAAATT 
GAL.rev ATACCTAGGTTTTTTCTCCTTGACGTTAAAGTATAGAG 
GAL2ko.fwd CATTAATTTTGCTTCCAAGACGACAGTAATATGTCTCCTACAATACCAGTGTCGGGGCTGGCTTAACTATGCGGCATCA 
GAL2ko.rev TATATGTACACAAATAATAGGTTTAGGTAAGGAATTTATATAATCGTAAGCTGGCTTATCGAAATTAATACGACTCACTA 
GAL2sc.fwd TGTGCATGTTATCTATATCCTTCTTTATATAGATGCTGTT 
GAL2sc.rev ATTAATTGTATGTTAGCTCAGGAATTCAACTGGAAGAAAG 
RTGFP.fwd GCCATGCCAGAAGGTTATGT 
RTGFP.rev ACCATTCTTTTGTTTGTCAGCC 
RT6OMT.fwd CTCATTAGCTCCACCAGCTAAGTA 
RT6OMT.rev GGTCAAACCGTCGCCTAAAT 
RTCNMT.fwd CAAAGTGCGGGTTACTACACTG 
RTCNMT.rev TCCACAGAACTTGTAACTCCAGT 
RT4'OMT.fwd GGTGCCGATGATACTAGGCA 
RT4'OMT.rev CCATTCCTTCATTAAACAACTGGC 
ACT1.fwd GGCATCATACCTTCTACAACGAAT 
ACT1.rev GGAATCCAAAACAATACCAGTAGTTCTA 
Supplementary Table 3. Summary of yields of benzylisoquinoline alkaloids. Yields are reported from the supernatant of 
growth cultures of the appropriate strains fed 5 mM norlaudonosoline.  
 
BIA compound yield (μM) yield (mg l-1) 
(R, S)-reticuline 500 164.5 
(S)-scoulerine 200 65.4 
(S)-tetrahydrocolumbamine 200 68.2 
(S)-tetrahydroberberine 100 33.9 
salutaridine 75 24.5 
 
 
SUPPLEMENTARY METHODS 
 
Construction of BIA expression vectors. Briefly, we constructed BIA expression 
vectors from the yeast shuttle vectors pCM185 and pCM1801, which harbor an ampicillin 
resistance marker for maintenance in E. coli, URA3 and TRP1 selection markers, 
respectively, and a centromeric (CEN4/ARS1) yeast origin of replication. To construct 
exemplary vectors (Supplementary Fig. 1), the TEF1 promoter and the CYC1 
terminator were amplified from p413-TEF2 and pCM1901, respectively, and assembled 
with the P. somniferum CNMT coding sequence using a PCR-based assembly strategy3. 
Primers that fused the DNA fragments included unique restriction sites to facilitate 
replacement of the coding sequences, and end primers included restriction sites for 
cloning into the plasmid backbones. We cloned the first promoter-gene-terminator DNA 
fragment into XhoI/BamHI sites of pCM185. A second DNA fragment containing the 
TEF1 promoter and P. somniferum 6OMT gene was assembled using similar PCR-based 
methods and cloned into PmeI/NotI sites preceding a CYC1 terminator on the plasmid 
backbone. The XhoI/NotI fragment containing dual promoter-gene-terminator sequences 
was excised from this vector and ligated into pCM180 to construct an analogous vector 
with a TRP1 selection marker. We replaced the low copy origin of replication with the 2 
μM origin from pCM190 using standard cloning procedures. We cloned coding 
sequences for various BIA enzymes into these standard vectors and altered restriction 
sites on the plasmid backbone(s) as necessary using the QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions. Single-gene 
constructs were made by excising one of the genes using appropriate restriction enzymes 
and blunting the ends with Klenow prior to ligation as needed, or cloning the desired 
coding sequence between the first promoter and second terminator in the standard vectors 
using SacII/NotI sites. 
 
 
Chromosomal integration of enzyme constructs. The plasmids pUG6, pUG27, pUG72, 
and pUG734 (EUROSCARF) contain geneticin resistance, S. pombe his5+, 
Kluyveromyces lactis URA3, and K. lactis LEU2 genes, respectively, flanked by loxP 
sites and were used in the construction of the integration cassettes. We amplified and 
assembled the TEF1 promoter and CYC1 terminator using PCR-based methods and the 
primers TEF.fwd, TEF.rev, CYC1.fwd, and CYC1.rev (Supplementary Table 2). The 
assembled DNA insert contained a multi-cloning site and was subcloned upstream of the 
selection marker in each construct. We cloned cDNAs into the multi-cloning site and 
amplified the entire integration cassette in two PCR steps using “A” and “B” primer sets 
to add ~80 nt of homology (Supplementary Table 2). We gel purified integration 
cassettes using the Zymoclean Gel DNA Recovery Kit (Zymo Research) according to the 
manufacturer’s instructions prior to transformation into the appropriate yeast strain. 
Integration of the cassettes into the correct locus was confirmed by PCR analysis of the 
targeted region of the chromosome. To remove all selection markers from the final 
strains, we transformed cells with the plasmid pSH63 which expresses a GAL-inducible 
Cre recombinase4. Cells harboring the plasmid were induced with galactose for 24 h and 
then transferred to YPD media to remove the selection pressure for plasmid maintenance. 
We isolated and restreaked single colonies on appropriate media to verify the loss of 
selection markers. 
 
 
Enzyme titration studies. We built template plasmids for chromosomal integrations for 
the enzyme titration studies by cloning the GAL1-10 promoter (amplified from pRS314-
GAL5 using primers GAL.fwd and GAL.rev) in place of the TEF1 promoter in pUG-
based plasmids. Construction of strains using the GAL1-10 promoter to control 
expression of single enzymes was analogous to that described for the TEF1 promoter 
strains with a final step to replace the GAL2 locus with the his5+ selection marker using a 
cassette amplified from pUG27 with primers GAL2ko.fwd and GAL2ko.rev. We 
confirmed integration into the targeted site with primers GAL2sc.fwd and GAL2sc.rev 
(Supplementary Table 2).  
For the enzyme titration assays, GAL-inducible strains were grown overnight in 
synthetic complete media containing all amino acids with 2% raffinose (w/v), 1% sucrose 
(w/v) as a sugar source. Galactose was added to the media at the appropriate 
concentration from a 10X stock at the time of back dilution and the norlaudanosoline 
substrate was added to a final concentration of 1 mM following an induction period of 4 
h. We sampled aliquots of the growth media for LC-MS/MS analysis 24 h after substrate 
addition. Data is reported as reticuline production measured by LC-MS peak area. 
Fluorescence quantification. For fluorescence measurements of CSY428 and CSY429 
(Fig. 4b and Supplementary Table 1), overnight cultures were grown in synthetic 
complete media with either 2% dextrose or 2% raffinose and 1% sucrose (noninducing-
nonrepressing), respectively. Cells were backdiluted into fresh media containing either 
dextrose (CSY428) or noninducing-nonrepressing media supplemented with the 
appropriate galactose concentration from a 10X stock (CSY429). We measured 
fluorescence (excitation 485 nm, emission 515 nm) and OD600 values on a fluorescence 
plate reader (TECAN, Safire). Fluorescence values were normalized using the OD600 
reading and values from a no stain control (wild-type cells) were subtracted. We used the 
resulting trend between relative fluorescence and galactose concentration as a guideline 
to estimate relative protein expression levels in our titratable strains.  
 
 
Analysis of protein levels through Western blotting. We constructed plasmids for 
Western blotting experiments by cloning the C-terminal epitope tag(s) from pYES-NT/A 
(Invitrogen) into a standard BIA expression vector followed by subcloning of the enzyme 
of interest. We transformed individual plasmids into wild-type yeast cells using a 
standard lithium acetate protocol. Overnight cultures were grown and backdiluted 1:100 
into 100 ml cultures. Cells were grown to OD600 ~1.2 and pelleted by centrifugation. The 
media was removed and cells were washed in 1 ml PBS, pelleted, and resuspended in 0.5 
ml Y-PER plus HALT protease inhibitor (Pierce). Cells were vortexed for ~20 min and 
the lysate separated by centrifugation. We estimated total protein using the Coomassie 
Plus Protein Assay Reagent (Pierce) and loaded ~50 μg of each sample onto a protein gel. 
We used NuPage 4-12% Bis-Tris gels with MES running buffer and transfer buffer 
according to the manufacturer’s instructions (Invitrogen). Proteins were blotted onto a 
nitrocellulose membrane (Whatman) using a semi-dry transfer cell (Bio-Rad) for 20 min 
at 15 V. We incubated the membrane with the Anti-V5 HRP antibody (Invitrogen) 
according to the manufacturer’s instructions (Invitrogen) with 5% nonfat milk as the 
blocking agent. Proteins were detected with the West Pico Super Signal Detection kit 
(Pierce) and imaged on a ChemiDoc XRS system (Bio-Rad). The image shown is 
representative of at least two independent experiments. 
 
 
Analysis of transcript levels through qRT-PCR. We extracted total RNA from yeast 
cells grown in 10 ml cultures to OD600 ~0.5 using standard acid phenol extraction 
procedures6. Briefly, cells were pelleted, frozen in liquid nitrogen, and resuspended in a 
50 mM NaOAc (pH 5.2) and 10 mM EDTA buffer. Cells were lysed by adding SDS to a 
final concentration of 1.6% and equal volume of acid phenol and incubating for 10 min at 
65°C with intermittent vortexing. Following cooling on ice, the aqueous phase was 
extracted and further extraction was carried out with an equal volume of chloroform. 
RNA samples were ethanol precipitated and resuspended in water, and total RNA was 
quantified on a NanoDrop according to the manufacturer’s instructions. RNA samples 
were treated with DNase (Invitrogen) according to the manufacturer’s instructions.  
We performed cDNA synthesis using gene-specific primers (Supplementary 
Table 2) and Superscript III Reverse Transcriptase (Invitrogen) according to the 
manufacturer’s instructions with 5 μg total RNA used in each reaction. Relative transcript 
levels were quantified from the cDNA samples by employing an appropriate primer set 
and the iQ SYBR Green Supermix (Bio-Rad) according to the manufacturer’s 
instructions on an iCycler iQ qRT-PCR machine (Bio-Rad). We analyzed the resulting 
data with the iCycler iQ software according to the manufacturer’s instructions. We 
normalized transcript levels to that of the endogenous ACT1 gene7 using ACT1-specific 
primers. Data are reported as the mean ± s.d. from at least two independent experiments. 
 
 
Analysis of stereoisomer forms of BIA metabolites through capillary 
electrophoresis-based chiral separation. We performed chiral analysis of 
norlaudanosoline, laudanosoline, and reticuline using the P/ACE MDQ Capillary 
Electrophoresis (CE) system (Beckman-Coulter). A bare fused silica capillary (50 μm 
i.d.) with 31.0 cm effective length (41 cm total) was used. We tested buffer solutions 
from the chiral test kit (Beckman) with the substrates norlaudanosoline and laudanosoline 
and optimized conditions using the HS-β-CD separation buffer at 5% (w/v) according to 
the manufacturer’s instructions. Injection was for 5 psi for 10 sec and voltage separation 
was performed at 15 kV. A diode array detector (PDA) module was used with the spectra 
presented taken at 280 nm. Representative data is shown from at least two independent 
experiments. 
For analysis of reticuline and other BIA metabolites, we developed HPLC 
methods to use water as the aqueous buffer rather than 0.1% acetic acid to avoid 
unnecessary noise in the CE spectra. Samples were run on a ZORBAX SB-Aq 3 x 250 
mm, 5 μm column with a gradient elution from 10% B to 90% B between 0 and 30 min 
where solvent B is methanol and solvent A is water. Reticuline elutes at 13 min using this 
method as confirmed by MS data. We collected fractions from 13.0-13.2 min and verified 
purity by re-running the sample(s) on LC-MS. Multiple fractions were collected and 
concentrated ~4 to 5-fold prior to CE analysis.  
 
 
Preparation of cell extracts. We prepared cell extracts by washing the cell pellets three 
times with PBS, adding 1 ml of cold methanol at -40°C, and vortexing with glass beads 
to disrupt the cells. Cell debris and glass beads were pelleted by centrifugation. The 
methanol was transferred to a clean tube and concentrated by evaporation to a final 
volume approximately equal to that of the original cell mass. 
 
 
Co-elution experiments with a known chemical standard. We performed co-elution 
experiments for the final metabolite synthesized by yeast in the sanguinarine and 
berberine branch. Authentic DL-canadin or (R, S)-tetrahydroberberine (Apin Chemicals 
Ltd) co-eluted with the product identified as (S)-tetrahydroberberine synthesized by 
engineered yeast cells at 26.9 min as determined by LC-MS/MS analysis. The m/z = 340 
extracted ion chromatograms are shown below for the known standard (50 mM; blue) and 
for the yeast growth media of CSY410 supplemented with 4 mM norlaudanosoline and 
grown for 48 h (red). MS/MS on the 340 ions showed the major ions m/z = 149 and m/z = 
175 in common. 
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